The effects of melatonin and memantine on brain injury after stroke
2010
0 görüntülenme
0 i̇ndirme
Danışman: Prof. Dr. Ertuğrul Kılıç
Özet (EN)
Melatonin and memantine are clinically used agents that have neuroprotectiveeffects against ischemic injury via antioxidative mechanisms and preventing excitotoxicity,respectively. In this study, a combination therapy including both melatonin and memantinewas used upon 90 minutes of transient focal cerebral ischemia and 24 hours reperfusion inmice. Twenty-four hours after cerebral ischemia, neurological deficit, infarct volume andbrain swelling were evaluated. Melatonin, memantine and melatonin/memantinecombination reduced the infarct volume significantly compared to vehicle treated controlgroup. In addition, melatonin and melatonin/memantine combination treatments decreasedbrain swelling upon ischemia significantly. Neurological deficit scores were significantlylower than the control group only in melatonin treated group. These results indicate thatmelatonin/memantine combination is a relevant and useful treatment option against stroke.
Yazar
Milas Uğur
Bu Yayına Nasıl Atıf Yapılır
Milas Uğur (Master Thesis). The effects of melatonin and memantine on brain injury after stroke, 2010, Yeditepe University.
Anahtar Kelimeler
Lisans
Tüm Hakları Saklıdır
Bu eser belirtilen lisans koşulları altında paylaşılmaktadır.
Yeditepe University tezlerinden daha fazlası
- Studies on cyclodextrin complexation of a poorly water soluble anti-hyperlipidemic drug, tablet formulation and characterization(2021)
- Washington ambassadors in Turkish-US relations (1927-1960)(2023)
- Metamorphosis of female voices: A study of the violation of women in Greek and Roman mythology and feminist rewritings reclaiming the narrative(2022)
- Knowledge distillation with foundation models for image segmentation(2023)
- The relationship between machiavelism, grandiose and vulnerable narcissism, and loneliness among white collar workers(2023)
- Evaluation of drug-drug interaction checkers along clinically relevant adverse drug events in oncology and hematology pediatric patients(2023)